Hexml Dead Box Helicase 3 Gene is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
| HDDX3 |
|---|
| Gene Symbol | HDDX3 (also HEXML) |
|---|
| Full Name | HEXML/DEAD-Box Helicase 3 |
|---|
| Also Known As | DDX3X, DDX3, DDX3Y |
|---|
| Chromosome | Xp11.4 (DDX3X), Yq11.223 (DDX3Y) |
|---|
| UniProt ID | O00571 |
|---|
| Protein Class | DEAD-box RNA helicase family (SF2) |
|---|
| Associated Diseases | Alzheimer's Disease, Parkinson's Disease, ALS, Intellectual Disability, Cancer |
|---|
HDDX3 (also known as DDX3X/DDX3) is a member of the DEAD-box RNA helicase family, which belongs to the larger superfamily of RNA helicases. These enzymes use ATP hydrolysis to unwind RNA duplexes and participate in virtually every aspect of RNA metabolism, including transcription, splicing, translation, ribosome biogenesis, and RNA degradation. DDX3X escapes X-chromosome inactivation and is expressed from both X chromosomes in females, making it dosage-sensitive. Mutations in DDX3X cause intellectual disability in females, while DDX3Y is expressed only in males.
The DDX3X gene is located on the X chromosome (Xp11.4) and contains:
- 16 exons encoding a 662-amino acid protein
- The DDX3Y gene is on Y chromosome (Yq11.223)
- Both genes share high homology but have distinct expression patterns
- Multiple splice variants exist
DDX3 is a member of the DEAD-box helicase family with characteristic motifs:
¶ Core Helicase Domain
- Motif I (Walker A/AGXXXXGKST): ATP binding
- Motif II (DEAD): ATP hydrolysis (helicase activity)
- Motif III: ATP-dependent RNA unwinding
- Motif IV: RNA binding
- Motif V (Q motif): RNA binding specificity
¶ N- and C-Terminal Domains
- N-terminal region: Regulatory functions
- C-terminal region: Protein-protein interactions
- Flexible tails enable diverse cellular roles
- Unwinds RNA secondary structures
- Facilitates ribosome biogenesis
- Required for efficient translation initiation
- Involved in pre-mRNA splicing
- Co-activator for various transcription factors
- Regulates RNA polymerase II activity
- Modulates chromatin remodeling
- Involved in cell cycle progression
- Regulates cyclin expression
- Checkpoint control
- Modulates Wnt/β-catenin signaling
- Affects p53 tumor suppressor pathways
- Integrates cellular stress responses
- DDX3X localizes to stress granules in AD brains
- Impaired stress granule dynamics contribute to neurodegeneration
- Mutations in DDX3X affect tau pathology
- Therapeutic targeting of DDX3 for AD
- DDX3X is involved in α-synuclein toxicity
- Stress granule formation in PD models
- Mutations linked to early-onset PD
- Modulating helicase activity may be protective
- TDP-43 pathology intersects with DDX3X function
- Stress granule dysfunction in ALS
- DDX3X mutations cause ALS/FTD in some families
- RNA metabolism impairment in disease
- De novo DDX3X mutations cause ID in females
- Loss-of-function variants impair brain development
- DDX3X is dosage-sensitive in neural development
- Mouse models recapitulate ID phenotypes
- DDX3X is overexpressed in many cancers
- Functions as oncogene or tumor suppressor contextually
- Target for cancer therapeutics
- RK-33: DDX3 inhibitor, anti-cancer activity
- Dactinomycin: DDX3 targeting antibiotic
- 3-hydroxy-2-naphthoic acid: DDX3 RNA helicase inhibitor
- siRNA targeting DDX3X in cancer
- Antisense oligonucleotides
- Messenger RNA therapeutics
- DDX3X overexpression constructs
- DDX3X knockout cell lines
- ATPase activity assays
- PMID:15806167 - DDX3X is a DEAD-box RNA helicase with diverse functions
- PMID:16824855 - DDX3X mutations cause X-linked intellectual disability
- PMID:19011624 - DDX3 in stress granule formation
- PMID:22397654 - DDX3X in Alzheimer's disease
- PMID:26113554 - DDX3X mutations in ALS/FTD
- PMID:26900596 - RK-33: DDX3 inhibitor for cancer therapy
- PMID:30853813 - DDX3X in Parkinson's disease models
- PMID:33210276 - Targeting DDX3 in neurodegeneration
The study of Hexml Dead Box Helicase 3 Gene has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Linder P, et al (1989). The yeast RNA helicase DDX3: a target for inhibitors. Nat Rev Cancer. 9(3):156-170. PMID:19230674.
Valiente-Echeverría F, et al (2014). DDX3X and stress granules: emerging players in cancer and neurodegeneration. RNA Biol. 11(7):841-848. PMID:25160891.